VOBIWIN TRIO FORTE 1 Tablet 15s
* 15 Tablet(s) in a Strip
* Mkt: Ranmarc Labs
* Country of Origin: India
* Delivery charges if applicable will be applied at checkout
VOBIWIN TRIO FORTE 1 TABLET is a combination of Glimepiride, Metformin and Voglibose which belongs to the group of medicines called Antidiabetic Agents. VOBIWIN TRIO FORTE 1 TABLET is used in adults to treat type 2 diabetes mellitus when diet, exercise and single agents/ second line therapy with two drugs are insufficient to adequately control blood sugar level.
VOBIWIN TRIO FORTE 1 TABLET is not recommended for use in patients allergic to glimepiride, metformin, voglibose, and/or other sulfonylureas/sulphonamides. It is also not recommended for use in patients with acute conditions (such as dehydration, severe infection), severe ketosis (severe complication of diabetes), severe trauma, lung problems (such as acute/chronic respiratory failure), heart problems (such as acute/chronic cardiac failure, recent myocardial infarction), and/or severe kidney/liver problems.
Before taking VOBIWIN TRIO FORTE 1 TABLET, inform your doctor if you recently had trauma, and/or have febrile infections, fever, uncontrolled diabetes, hypothyroidism (underactive thyroid), chronic intestinal disease, fever, other kidney/liver problems.
VOBIWIN TRIO FORTE 1 TABLET is not recommended for use in pregnant and breastfeeding women since it may cause harm to the developing foetus/nursing child.
VOBIWIN TRIO FORTE 1 TABLET is also not recommended for use in children and adolescents (aged below 18 years) and is advised to be used with caution in elderly patients (aged 75 years/above) after consulting the doctor.
The most common side-effects of VOBIWIN TRIO FORTE 1 TABLET are nausea and vomiting, diarrhoea, abdominal pain, loss of appetite, metallic taste, and/or hypoglycaemia (low blood sugar). Consult your doctor if any of these side effects worsens.
USES OF VOBIWIN TRIO FORTE 1 TABLET
- Treats type 2 diabetes mellitus in adults when diet, exercise and single agents/ second line of therapy with two drugs are insufficient to adequately control blood sugar level
There are no reviews yet.